Tarveda was founded by leaders from MIT and Harvard Medical School with a shared vision to leverage the latest advances in mechanism-driven drug design and chemistry to enable a innovation in drug therapies. Tarveda’s founders provide scientific leadership and expertise to support the company’s promising new approach to create integrative, pharmacologically optimized medicines that more predictably, effectively, and safely target the multiple mechanisms underlying complex diseases.

Omid Farokhzad
Omid Farokhzad

Associate Professor, Harvard Medical School

  • Internationally recognized expert in the field of nanomedicine
  • Inventor on more than 140 issued/pending U.S. and international patents, including the foundational intellectual property for Tarveda and two other venture-backed, clinical-stage biotechnology companies: BIND Biosciences and Selecta Biosciences
Robert Langer
Robert Langer

David H. Koch Institute Professor, MIT

  • Preeminent pioneer in the fields of materials science and polymeric drug delivery
  • Recipient of more than 210 major awards, including the 2006 U.S. National Medal of Science, and one of few individuals elected to all three U.S. National Academies
Stephen J. Lippard
Stephen Lippard

Arthur Amos Noyes Professor of Chemistry, MIT

  • A major contributor to the fields of bioinorganic and medicinal inorganic chemistry
  • Recipient of numerous prestigious awards, including the 2004 National Medal of Science, and a member of the National Academy of Sciences, Institute of Medicine, and American Academy of Arts and Sciences